Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide

E. Campora, A. Vidali, S. Mammoliti, N. Ragni, P. F. Conte

Research output: Contribution to journalArticlepeer-review

Abstract

Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m 2 IV) and cyclophosphamide (600 mg/m 2 IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.

Original languageEnglish
Pages (from-to)181-183
Number of pages3
JournalEuropean Journal of Gynaecological Oncology
Volume11
Issue number3
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide'. Together they form a unique fingerprint.

Cite this